The subgroup meta-regression analysis of early treatment trials confirmed T2DM as a significant moderator in this population (β = − 0.0057, p = 0.0016, R2 = 99.9%), highlighting its pivotal role when SGLT2 inhibitors are administered early following an AMI. Here, SLC5A2 is linked to type 2 diabetes mellitus.